Free Trial Information
BioCentury | Nov 17, 2017
Clinical News

Sangamo doses first patient in Phase I/II in vivo gene editing trial

...9 patients with MPS II at various U.S. hospitals. The first patient was treated at UCSF Benioff Children's Hospital Oakland...
Read More
BioCentury | Nov 16, 2017
Clinical News

Sangamo doses first patient in gene editing study

...nine patients with MPS II at various U.S. hospitals. The first patient was treated at UCSF Benioff Children's Hospital Oakland...
Read More
BioCentury | Nov 25, 2013
Product Development

Golden State IRB

...Irvine, Los Angeles and San Diego, Stanford University , the University of Southern California , Children's Hospital & Research Center Oakland...
...Center , San Francisco, Calif. Cancer Prevention & Research Institute of Texas (CPRIT), Austin, Texas Children's Hospital & Research Center Oakland...
Read More
BioCentury | Mar 18, 2013
Company News

Bayer, Children's Hospital & Research Center Oakland deal

...research efforts. The hospital could not be reached for details. Bayer AG (Xetra:BAYN), Leverkusen, Germany Children's Hospital & Research Center Oakland...
Read More
BioCentury | May 24, 2010
Clinical News

Trappsol hydroxypropyl-beta-cyclodextrin regulatory update

FDA granted Orphan Drug designation to the hospital for Trappsol hydroxypropyl-beta-cyclodextrin (HPBCD) to treat Niemann-Pick type C disease. Children's Hospital & Research Center , Oakland, Calif. Product: Trappsol hydroxypropyl-beta-cyclodextrin ( HPBCD ) Business: Metabolic WIR Staff...
Read More
BioCentury | Jan 17, 2005
Company News

BioVeris, Children's Hospital & Research Center deal

The hospital granted BIOV an option to exclusively license a vaccine against Neisseria meningitidis serogroup B. If BIOV exercises its option, the hospital will receive a license fee and potential milestones and royalties. Also, BIOV...
Read More
Items per page:
1 - 6 of 6
BioCentury | Nov 17, 2017
Clinical News

Sangamo doses first patient in Phase I/II in vivo gene editing trial

...9 patients with MPS II at various U.S. hospitals. The first patient was treated at UCSF Benioff Children's Hospital Oakland...
Read More
BioCentury | Nov 16, 2017
Clinical News

Sangamo doses first patient in gene editing study

...nine patients with MPS II at various U.S. hospitals. The first patient was treated at UCSF Benioff Children's Hospital Oakland...
Read More
BioCentury | Nov 25, 2013
Product Development

Golden State IRB

...Irvine, Los Angeles and San Diego, Stanford University , the University of Southern California , Children's Hospital & Research Center Oakland...
...Center , San Francisco, Calif. Cancer Prevention & Research Institute of Texas (CPRIT), Austin, Texas Children's Hospital & Research Center Oakland...
Read More
BioCentury | Mar 18, 2013
Company News

Bayer, Children's Hospital & Research Center Oakland deal

...research efforts. The hospital could not be reached for details. Bayer AG (Xetra:BAYN), Leverkusen, Germany Children's Hospital & Research Center Oakland...
Read More
BioCentury | May 24, 2010
Clinical News

Trappsol hydroxypropyl-beta-cyclodextrin regulatory update

FDA granted Orphan Drug designation to the hospital for Trappsol hydroxypropyl-beta-cyclodextrin (HPBCD) to treat Niemann-Pick type C disease. Children's Hospital & Research Center , Oakland, Calif. Product: Trappsol hydroxypropyl-beta-cyclodextrin ( HPBCD ) Business: Metabolic WIR Staff...
Read More
BioCentury | Jan 17, 2005
Company News

BioVeris, Children's Hospital & Research Center deal

The hospital granted BIOV an option to exclusively license a vaccine against Neisseria meningitidis serogroup B. If BIOV exercises its option, the hospital will receive a license fee and potential milestones and royalties. Also, BIOV...
Read More
Items per page:
1 - 6 of 6